FY2025 Earnings Forecast for Neogen Issued By Zacks Research

Key Points

• Zacks Research has revised its FY2025 earnings estimate for Neogen Corporation, lowering it from $0.31 to $0.29 per share, while the consensus estimate remains at $0.38.
• Neogen's stock price has seen a decrease, with brokerages like Guggenheim and Piper Sandler reducing their price targets to $10.00 and $5.00 respectively.
• Recent insider activity includes Director Aashima Gupta acquiring 16,000 shares at an average price of $6.25 per share, increasing her ownership by 270.41%.

Neogen Corporation (NASDAQ:NEOG - Free Report) - Equities research analysts at Zacks Research lowered their FY2025 earnings estimates for shares of Neogen in a report released on Wednesday, July 23rd. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of $0.29 for the year, down from their prior estimate of $0.31. The consensus estimate for Neogen's current full-year earnings is $0.38 per share. Zacks Research also issued estimates for Neogen's Q4 2025 earnings at $0.06 EPS, Q1 2026 earnings at $0.07 EPS, Q4 2026 earnings at $0.10 EPS and FY2027 earnings at $0.43 EPS.

Several other brokerages have also recently weighed in on NEOG. Guggenheim decreased their price target on Neogen from $13.00 to $10.00 and set a "buy" rating on the stock in a research report on Monday, June 30th. Piper Sandler reduced their price target on shares of Neogen from $6.40 to $5.00 and set a "neutral" rating on the stock in a research report on Tuesday, April 22nd.

Neogen Price Performance

NEOG opened at $5.12 on Friday. The company has a debt-to-equity ratio of 0.33, a current ratio of 3.91 and a quick ratio of 2.45. The company has a market capitalization of $1.11 billion, a price-to-earnings ratio of -2.30 and a beta of 1.77. The firm's fifty day moving average price is $5.40 and its two-hundred day moving average price is $7.60. Neogen has a 1 year low of $3.87 and a 1 year high of $18.58.

Institutional Investors Weigh In On Neogen

A number of large investors have recently made changes to their positions in the company. Vanguard Group Inc. boosted its position in shares of Neogen by 8.8% during the 1st quarter. Vanguard Group Inc. now owns 23,550,128 shares of the company's stock valued at $204,180,000 after acquiring an additional 1,912,877 shares during the last quarter. Norges Bank purchased a new stake in Neogen in the fourth quarter worth $212,171,000. Gates Capital Management Inc. bought a new position in shares of Neogen during the 1st quarter worth $79,391,000. Conestoga Capital Advisors LLC grew its position in shares of Neogen by 0.4% during the 1st quarter. Conestoga Capital Advisors LLC now owns 8,540,859 shares of the company's stock worth $74,049,000 after buying an additional 37,271 shares in the last quarter. Finally, Bamco Inc. NY grew its position in shares of Neogen by 16.2% during the 4th quarter. Bamco Inc. NY now owns 8,485,308 shares of the company's stock worth $103,012,000 after buying an additional 1,182,193 shares in the last quarter. 96.73% of the stock is currently owned by institutional investors.

Insider Activity

In other Neogen news, Director Aashima Gupta acquired 16,000 shares of Neogen stock in a transaction that occurred on Monday, May 12th. The stock was bought at an average cost of $6.25 per share, for a total transaction of $100,000.00. Following the acquisition, the director owned 21,917 shares of the company's stock, valued at $136,981.25. This represents a 270.41% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. 1.13% of the stock is currently owned by corporate insiders.

About Neogen

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.